anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Lipid accumulation in adipocytes occurs through multifactorial effects such as overnutrition due to unbalanced eating habits, reduced physical activity, and genetic factors. In addition, obesity can be intensified by the dis-regulation of various metabolic systems such as differentiation, lipogenesis, lipolysis, and energy metabolism of adipocytes. In this study, the Jeju roasted peel extract from Citrus unshiu S.Markov. (JRC), which is discarded as opposed to the pulp of C. unshiu S.Markov., is commonly consumed to ameliorate obesity. To investigate the anti-obesity effect of JRC, these studies were conducted on differentiated 3T3-L1 cells and in high-fat diet-induced mice, and related methods were used to confirm whether it decreased lipid accumulation in adipocytes. The mechanism of inhibiting obesity by JRC was confirmed through mRNA expression studies. JRC suppressed lipid accumulation in adipocytes and adipose tissue, and significantly improved enzymes such as alanine aminotransferase, aspartate aminotransferase, and gamma-glutamyl transferase and serum lipid profiles. In addition, it effectively modulated the expression of genes related to lipid and energy metabolism in adipose tissue. As a result, these findings suggest that JRC could be a therapeutic regulator of body fat accumulation by significantly alleviating the dis-regulation of intracellular lipid metabolism in adipocytes and by enhancement of energy metabolism (Approval No. CNU IACUC-YB-2023-98).
This invention relates to an anti-HIV and malignant tumor compounds and the preparation methods and application. The preparation method is: take quinolinic acid as raw materials, add the ether, 30% hydrogen peroxide, caustic soda and glacial acetic acid in turn; then under 150 to 255 deg heating and backstreaming for 1 to 2 hours; at last standing for 20 hours and separate out sediments to get these compounds. The present invention is improving on the basis previous studies of quinoline compounds which has anticancer and analgesic effect. And by animal experiments show that using this compound to treat animals which attacked by the current internationally recognized tumor virus strain ,after 70 days animals have survived in good shape and did not have any toxicological responses. This showed that the compounds has no side toxic effect, and has a clear anti-HIV and cancer role. In addition, the preparation method is simple and therefore suitable for large-scale industrial production.
Severe ﬂuid retention has been reported following docetaxel therapy. Patients should be premedicated with oral corticosteroids prior to each docetaxel administration to reduce the incidence and severity of ﬂuid retention [see Dosage and Administration (2.6)]. Patients with pre-existing effusions should be closely monitored from the ﬁrst dose for the possible exacerbation of the effusions.

When ﬂuid retention occurs, peripheral edema usually starts in the lower extremities and may become generalized with a median weight gain of 2 kg. 

Among 92 breast cancer patients premedicated with 3-day corticosteroids, moderate ﬂuid retention occurred in 27.2% and severe ﬂuid retention in 6.5%. The median cumulative dose to onset of moderate or severe ﬂuid retention was 819 mg/m². Nine of 92 patients (9.8%) of patients discontinued treatment due to ﬂuid retention: 4 patients discontinued with severe ﬂuid retention; the remaining 5 had mild or moderate ﬂuid retention. The median cumulative dose to treatment discontinuation due to ﬂuid retention was 1021 mg/m². Fluid retention was completely, but sometimes slowly, reversible with a median of 16 weeks from the last infusion of docetaxel to resolution (range: 0 to 42+ weeks). Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s).
Cediranib 20 mg once daily with olaparib 300 mg twice daily, continuously on a 28 day cycle for up to 6 cycles. Participants with stable disease or better will be able to continue with olaparib and cediranib until disease progression.
PURPOSE:To collect a remarkable amount of a physiologically active substance, by containing polyvinylpyrrolidone in an ordinary basal culture medium and cultivating lymphatic cells with a composition for multiplying lymphatic cells containing blood serum in a smaller amount than normal one or without adding the blood serum. CONSTITUTION:Polyvinylpyrrolidone having 10,000-1,200,000 average molecular weight is added to a basal culture medium used for cultivating lymphatic cells, e.g. Iscove's culture medium, Ham's culture medium, L-15 culture medium, etc., to give about 0.001-10% (wt./vol.) concentration to provide a composition for multiplying the lymphatic ells. Insulin, transferrin, ethanolamine, selenious acid, etc., may be added to the above-mentioned composition. Blood serum is not added or the amount thereof is less than the normal one if it added. Iymphatic ells, e.g. human, rat, mouse, cattle, etc., are cultivated with the above- mentioned composition to efficiently produce a physiologically active substance at a low cost.
The present invention relates to a medicine for treating upper respiratory tract infection and a preparation method thereof. The medicines in the prior art can not be typed according to the symptoms and signs of diseases. The medicine of the present invention is prepared from seven raw materials of 35 to 45 portions of bupleurum, 70 to 80 portions of kudzuvine root, 20 to 30 portions of baical skullcap root, 10 to 20 portions of ephedra herb, 25 to 35 portions of apricot kernel, 70 to 80 portions of plaster and 5 to 10 portions of liquoric root. The preparation method has the steps: putting bupleurum, kudzuvine root and baical skullcap root into a multifunctional extraction tank; adding alcohol into the multifunctional extraction tank; refluxing and extracting the mixture in the multifunctional extraction tank to obtain thick paste; putting ephedra herb, apricot kernel, plaster and liquoric root into the multifunctional extraction tank; adding alcohol for refluxing extracting and concentrating the mixture in the multifunctional extraction tank into thick paste; merging the two kinds of paste to obtain the medicine of the present invention. The medicine has the treating principle of expelling wind, relieving exterior syndromes and clearing heat and toxin, and has favorable curative effects on common cold, high fever, tussis, difficult phlegm coughing out, dry swallow, throat swelling and pain, rhinobyon, thirst, drink desire, etc. The present invention has the functions of scientific preparation method, simplified technology and enhanced reproducibility.
To investigate the causality between B cell count and psoriasis by Mendelian randomization (MR). Collected B cell count and psoriasis data from IEU Open GWAS Project. Employed inverse variance weighting (IVW), MR-Egger, WM, weighted mode for analysis, ensuring result robustness. Assessed horizontal pleiotropy with MR-Egger, detected outliers using MR-PRESSO and examined instrumental variables heterogeneity with Cochran's Q-test. The IVW method suggested an association between a genetically predicted memory B cell count and the risk of psoriasis vulgaris. IVW results also showed no causality between other exposure factors and the corresponding outcomes. Also, the global test of MR-PRESSO analysis showed a significant association between a genetically predicted transitional absolute B cell count and the lower risk of psoriasis vulgaris. MR-Egger regression showed that horizontal pleiotropy did not influence the analysis results. We found that memory B cell absolute counts are associated with a lower risk of psoriasis. These data further elucidate the role of memory B cells in psoriasis and provide new options for psoriasis treatment.
Patients undergo cryoablation and receive tremelimumab IV over 60 minutes at weeks 1 (2-6 days after cryoablation) and 5. Within 4-6 weeks later, patients undergo surgery or biopsy. After surgery or biopsy, patients receive tremelimumab IV Q34W for 3 doses, and then Q12W in the absence of disease progression or unacceptable toxicity.
PURPOSE: A method for producing an oral microcapsule by dispersing plant extracts having effects of preventing and treating oral disease in a water insoluble solvent and then spraying the obtained emulsion solution while cooling is provided. The effective component of the composition has enhanced stability and is slowly released and the composition, therefore, has excellent effects of preventing periodontal disease and dental cavity and inhibiting bad breath. CONSTITUTION: Rosin salt as an effective component for oral is dispersed in a water insoluble solvent in emulsion form in a weight ratio of 1:0.5 to 30 to produce an emulsion solution. Then, the emulsion solution is sprayed, cooled and then dried to produce a spherical oral microcapsule. The oral composition contains 0.05 to 5% by weight of the oral capsule, based on the total weight of the oral composition. The rosin salt is obtained by blending a pine needle extract and salt in a weight ratio of 1:0.1 to 10.
Repetitive transcranial magnetic stimulation (rTMS) is an FDA-approved and widely used focal, safe, well-tolerated, and non-invasive brain stimulation method for the treatment of depression, and has been approved in Canada. Typical clinical rTMS is delivered on the left dorsolateral prefrontal cortex (DLPFC) at a 10 Hz frequency over 30-45 minutes to induce an increase in cortical excitability, which outlasts the duration of stimulation. iTBS is a novel refinement of conventional rTMS. iTBS consists of bursts of 3 stimulations at 50 Hz at theta frequency (5 Hz). However, instead of 30 minute treatment sessions, iTBS has comparable clinical efficacy with only 3 minute treatment sessions. Currently roughly 50% of the people receiving rTMS treatment for depression respond to the treatment. One of the main goals of current research in rTMS is to find improvements in the protocol to increase the number of responders.

One of the potential ways to improve rTMS is to select the target based on individual resting state functional connectivity. Within the DLPFC, there are still several possible targets for the rTMS. Functional magnetic resonance imaging (fMRI) studies have shown that therapeutic effects of rTMS are related to its effects on the subgenual anterior cingulate cortex (sgACC; Broadman area 25). Past literature has shown that in MDD the effectiveness of a target is related to its connectivity with the sgACC. A recent study showed in a retrospective sample of MDD patients that response to rTMS correlates with the distance from the personalized connectivity-guided target rather than a group average target, opening the door for individualized connectivity-guided rTMS targeting. Yet, the question whether individualized connectivity-guided rTMS targeting improves rTMS outcomes in a prospective sample has never been investigated. In this two-arm triple-blind randomized parallel assignment clinical trial we will test if 6-week treatment using individualized connectivity-guided iTBS targeting leads to better outcomes in MDD compared to conventional neuronavigated iTBS.
NEW MATERIAL:A compound expressed by formula I [R is pyridyl or pyrimidinyl capable of having substituent group (alkyl or alkoxy); ring A is phenyl capable of having substituent group (halogen, alkyl, alkoxy or trihalogenoalkyl); Q is methylene or single bond; m is 1-4; n is 0-2] and acid addition salt thereof. EXAMPLE:(E)-1-Cinnamyl-3-(3-pyridyl)-2-imidazolidinone. USE:The aimed activator is used in treatment and prevention of several symptoms (e.g., senile dementia, lowering of spontaneity or delay of thought) based on nerve metabolism disorder or nerve metabolism abnormality. Further, the activator can be used also as an antisenile dementia drug, remedy for disturbance of memory, antidepressant. The dose is preferably 5-50mg/kg. body daily. PREPARATION:A compound expressed by formula II (X<1> is reactive residue) is condensed with a compound expressed by formula III to provide the compound expressed by formula I.
Global annual incidence of head and neck (HN) cancers is high. It is even a greater concern in West Indies compared to other American countries. Most represented histological type is squamous carcinoma and several risk factors are involved , including tobacco exposure. Moreover, it is now clear that Human Papillomavirus (HPV) is a causal factor in the development of HNSCCs : as many as 5 to 10% of tumors are induced by HPV in the world, and it is responsible of 25,9% of HN tumors. HPV 16 is the most involved (87%). However, HPV epidemiology is different in West Indies with the implication of various genotypes. Detection of HPV infection can be achieved through several methods such as polymerase chain reaction (PCR) or RNAscope, which is a new reliable precise technique which reflects the transcriptional activity of the virus. The differences between the genotype of HPV involved within both populations need to be consider to better identify therapeutic targets.Studying the microenvironment may allow a better understanding of anti-tumoral immunity and may help patient selection in order to achieved better responses to immunotherapy.
AIMS: Atrial fibrillation (AF) is the most common sustained arrhythmia among patients with hypertrophic cardiomyopathy (HCM), increasing symptom burden and stroke risk. We aimed to construct a plasma proteomics-based model to predict new-onset AF in patients with HCM and determine dysregulated signalling pathways.
METHODS AND RESULTS: In this prospective, multi-centre cohort study, we conducted plasma proteomics profiling of 4986 proteins at enrolment. We developed a proteomics-based machine learning model to predict new-onset AF using samples from one institution (training set) and tested its predictive ability using independent samples from another institution (test set). We performed a survival analysis to compare the risk of new-onset AF among high- and low-risk groups in the test set. We performed pathway analysis of proteins significantly (univariable P < 0.05) associated with new-onset AF using a false discovery rate (FDR) threshold of 0.001. The study included 284 patients with HCM (training set: 193, test set: 91). Thirty-seven (13%) patients developed AF during median follow-up of 3.2 years [25-75 percentile: 1.8-5.2]. Using the proteomics-based prediction model developed in the training set, the area under the receiver operating characteristic curve was 0.89 (95% confidence interval 0.78-0.99) in the test set. In the test set, patients categorized as high risk had a higher rate of developing new-onset AF (log-rank P = 0.002). The Ras-MAPK pathway was dysregulated in patients who developed incident AF during follow-up (FDR < 1.0 × 10-6).
CONCLUSION: This is the first study to demonstrate the ability of plasma proteomics to predict new-onset AF in HCM and identify dysregulated signalling pathways.
Patients in this arm will receive the investigating institution's current standard of care for patients with COVID-19. For example, all patients requiring supplemental oxygen (assuming no contraindications) would be candidates for both remdesivir 200 mg x 1 IV dose followed the next day by 100 mg q24h IV x up to 4 doses, as well as dexamethasone 6 mg q24h x 10 up to 10 doses.
This is a prospective, randomized, controlled, single-blind, single-center clinical trial. Patients with ST-segment elevation myocardial infarction (STEMI) who were admitted in the People's Liberation Army General Hospital were equally randomized to receive either cardiomyopeptidin or placebo, and patients in cardiomyopeptidin group are given the injection of cardiomyopeptidinl before primary percutaneous coronary intervention (PCI) and intravenous infusion of cardiomyopeptidin was performed 3 days after primary PCI. Myocardial perfusion flow grade was evaluated by the result of primary PCI. Myocardial infarct size, microvascular obstruction and salvage myocardium were evaluated by enhanced cardiac magnetic resonance (CMR). Major adverse cardiovascular events (nonfatal myocardial infarction, all-cause death, hospitalization for acute heart failure, and revascularization for angina) were observed during the 6-month follow-up. CMR is performed to evaluate the effect of cardiomyopeptidin before primary PCI on myocardial salvage and microcirculation perfusion in patients with STEMI.
A device for supporting prescription of auditory nerve diseases assists a medical professional in prescribing physical therapy including posture correction using image data of a user for auditory nerve diseases including tinnitus, hearing loss, and otolithiasis, so that user can expect hearing recovery. In a human ear, there is an auditory organ called cochlea. Accordingly, a state of auditory cells in the cochlea may be primarily related to tinnitus and hearing loss. However, secondarily, a process of smoothly delivering sound received by the auditory cells to brain is essential. If the delivery is not properly performed, users cannot help experiencing abnormalities in auditory functions such as tinnitus and hearing loss. The brain stem to which an auditory nerve is connected is a connecting line of spine, and if the spine is twisted, the brain stem is also twisted and affects an auditory function of a user. Therefore, the auditory function is restored only when the twisted spine is corrected correctly, and accordingly, auditory nerve diseases such as tinnitus, hearing loss, and otolithiasis can be treated. The device for supporting prescription of auditory nerve diseases according to an embodiment of the present invention can maximize an effect of improving a hearing function of a user by prescribing not only herbal medicine treatment based on oriental medicine, but also physical therapy including posture correction.
FIELD: medicine, in particular, medical cosmetology. SUBSTANCE: cream containing natural bee wax, stabilizer, fat and water phases, additionally has mother milk. Used as a stabilizer is concentrate of biologically active components of isoprenoid and phenylpropanoid row separated from propolis at the following ratio of components, mas.%: natural bee wax, 2-15; mother milk, 0.1-0.5; concentrate of biologically active components separated from propolis, 0.1-3.0; fat phase, 40-60; water phase, the balance. Used as fat phase are natural vegetable and/or animal oils. Presence of mother milk in cream allows to use it for stimulation of metabolic process in skin, its restoration and rejuvenation. EFFECT: higher efficiency. 2 cl
Inflammatory bowel disease (IBD) is a common chronic disease with a complex etiology, characterized by body weight loss, intestinal barrier damage, and an imbalance of intestinal flora, posing a significant threat to people's health. In this work, we studied whether safer natural active agaro-oligosaccharides (AOSs) benefit mice with IBD and elucidated their underlying mechanisms. The findings indicated that oral administration of agarobiose (A2), agarotriose (A3), and agarotetraose (A4) contributed to alleviating body weight loss and colon shortening, as well as enhancing IL-10 levels while reducing IL-6, IL-1β, and TNF-α. AOSs improved colon disruption, reduced the number of goblet cells caused by DSS, and enhanced the expression of Muc2, ZO-1, and occludin-1 to repair the intestinal barrier. It is noteworthy that A3 demonstrated superior outcomes in the evaluated AOSs relative to A2 and A4. This was evidenced by an increase in Bacteroidota and reduced Firmicutes at the phylum level, which corrected DSS-induced intestinal dysbiosis and significantly restored disrupted metabolic pathways, including amino acid and lipid metabolism. The differential metabolites between the AOS treatment groups and the model group were mainly enriched in arginine synthesis with co-regulated critical substances N-acetyl-L-citrulline and N2-acetylornithine, which alleviated colitis. This evidence offers a fresh perspective on the potential application of AOSs as functional foods to improve intestinal inflammation and metabolism.
The invention relates to compositions containing recycling/transfer proteins for structurally/functionally modified lipids, a lipid depot of structurally non-modified lipids, and non-transferable active ingredients. Such compositions can be used for the engineering of biomembranes, e.g. by external topical application, especially to the skin/mucous membranes. Structurally or functionally, especially oxidatively modified, lipids are removed from the structures containing the same, such as lipid aggregates of the skin, are externally regenerated in a depot, and preferably introduced back into the structures. The invention also relates to the recycling of modified lipids of biomembranes. The inventive compositions are self-regulative and can be especially applied in a cosmetic, cosmetic balneological or dermatological/pharmaceutical manner.
BACKGROUND Severe pre-eclampsia (sPE) and postpartum hemorrhage (PPH) in pregnancy have serious impact on maternal and fetal health and life. Co-occurrence of sPE and PPH often leads to poor pregnancy outcomes. We explored risk factors associated with PPH in women with sPE. MATERIAL AND METHODS This retrospective study included 1953 women with sPE who delivered at the Women's Hospital of Nanjing Medical University between April 2015 and April 2023. Risk factors for developing PPH in sPE were analyzed, and subgroups were analyzed by delivery mode (cesarean and vaginal). RESULTS A total of 197 women with PPH and 1756 women without PPH were included. Binary logistic regression results showed twin pregnancy (P<0.001), placenta accreta spectrum disorders (P=0.045), and placenta previa (P<0.001) were independent risk factors for PPH in women with sPE. Subgroup analysis showed risk factors for PPH in cesarean delivery group were the same as in the total population, but vaginal delivery did not reduce risk of PPH. Spinal anesthesia reduced risk of PPH relative to general anesthesia (P=0.034). Vaginal delivery group had no independent risk factors for PPH; however, magnesium sulfate (P=0.041) reduced PPH incidence. CONCLUSIONS Women with twin pregnancy, placenta accreta spectrum disorders, placenta previa, and assisted reproduction with sPE should be alerted to the risk of PPH, and spinal anesthesia should be preferred in cesarean delivery. Magnesium sulfate should be used aggressively in women with sPE; however, the relationship between magnesium sulfate and PPH risk needs further investigation.
In a 6-month bioassay, reslizumab was administered intravenously once every 2 weeks for 26 consecutive weeks (14 total doses) to Tg.rasH2 mice at doses up to 516 mg/kg/dose. There was no evidence of carcinogenicity.

Published literature using animal models suggests that IL-5 and eosinophils are part of an early inflammatory reaction at the site of tumorigenesis and can promote tumor rejection. However, other reports indicate that eosinophil infiltration into tumors can promote tumor growth. Therefore, the malignancy risk in humans from an antibody to IL-5 such as reslizumab is unknown. 

In a fertility study, administration of reslizumab to parental mice at doses up to 50 mg/kg (approximately 6 times the MRHD on an AUC basis) had no effects on male or female mating or fertility.